Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Total Liabilities (2018 - 2025)

Black Diamond Therapeutics' Total Liabilities history spans 6 years, with the latest figure at $30.8 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 21.74% year-over-year to $30.8 million; the TTM value through Dec 2025 reached $30.8 million, down 21.74%, while the annual FY2025 figure was $30.8 million, 21.74% down from the prior year.
  • Total Liabilities reached $30.8 million in Q4 2025 per BDTX's latest filing, down from $31.6 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $55.2 million in Q3 2021 to a low of $30.8 million in Q4 2025.
  • Average Total Liabilities over 3 years is $37.5 million, with a median of $36.9 million recorded in 2021.
  • Peak YoY movement for Total Liabilities: skyrocketed 482.8% in 2021, then decreased 21.96% in 2025.
  • A 3-year view of Total Liabilities shows it stood at $55.2 million in 2021, then decreased by 28.68% to $39.4 million in 2024, then decreased by 21.74% to $30.8 million in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Total Liabilities are $30.8 million (Q4 2025), $31.6 million (Q3 2025), and $33.8 million (Q2 2025).